Dupixent (dupilumab) - Sanofi, Regeneron
Real-world evidence on dupilumab dose spacing and tolerability in children with atopic dermatitis. (PubMed, Eur J Dermatol) - Oct 23, 2026 - No abstract available 
HEOR • Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
http://www.ncbi.nlm.nih.gov/pubmed/42904793
 
Aude Huitric; Célia Delesalle; Claire Abasq-Thomas; Emilie Brenaut; Laurent Misery; Pierrick Cros
 
Oct 23, 2026
 
Prev Next